Page URL:

Breast cancer blood test tracks treatment response

18 March 2013
Appeared in BioNews 697

A blood test is being developed that could help doctors monitor how breast cancer tumours respond to therapy.

'These results hold the promise of a system that could allow us to modify someone's treatment as their cancer changes', says Professor Peter Johnson, the chief clinician at Cancer Research UK, which part-funded the study.

Currently, biopsies and scans are used to monitor tumours during treatment, but these can be slow and don't always provide reliable information. Results from an early study indicate that this blood test could potentially provide a faster, more reliable, and less invasive alternative. The test is among a growing number being developed for several aspects of cancer diagnosis (see BioNews 656 and 677).

Scientists tested the blood of 30 women with an advanced form of cancer called metastatic breast cancer. The blood was screened for several cancer components, called biomarkers. These included a cancer protein, tumour DNA, and whole tumour cells circulating in the blood. The levels of each were compared with the disease's progression, as assessed by computerised tomography (CT) scans.

They discovered that the amount of one biomarker, tumour DNA, correlated well with the extent of the cancer: the more the disease progressed, the more tumour DNA there was in the blood sample.

'Fragments of DNA are shed by cancer cells when they die, meaning they can be detected in blood samples using sensitive new sequencing techniques', says Professor Carlos Caldas of the Cancer Research UK Cambridge Institute, who co-led the study. 'The levels of tumour DNA tell us how the cancer is responding to treatment'.

The test works by checking the blood sample for two mutated genes, which are commonly associated with tumours. However, not all breast cancers have mutations in these genes. In fact, 52 women with metastatic breast cancer were recruited for the study, but only 30 of the women had tumours with the mutations used in the test. This limits the usefulness of the test to women whose tumour cells carry these specific mutations.

Metastatic breast cancer is currently incurable. Treatment is intended to extend the patient's lifespan, rather than eliminate the cancer. It is therefore hoped that the blood test could supplement CT scans to improve the quality of life of these patients. 'By understanding the point at which a cancer changes we can select the most effective treatments and minimise side effects for patients', says Professor Caldas.

The results, published in the New England Journal of Medicine, are from a small pilot study. There are plans for a larger, randomised trial to determine whether the test could change how the cancer is treated or improve patient survival times.

Professor Daniel Haber of Massachusetts General Hospital Cancer Center, who was not involved in the study, told Nature News: 'This is a powerful technology. It can be very scalable, inexpensive, and useful'.

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
The New England Journal of Medicine |  13 March 2013
Blood test reveals women's response to breast cancer treatment
Cancer Research UK (press release) |  13 March 2013
Blood test shows if breast cancer therapy is working and allow treatment to be tailored to each individual sufferer
Mail Online |  14 March 2013
Blood test tracks cancer
Nature News |  13 March 2013
Cancer blood test 'on NHS in two years'
Daily Telegraph |  13 March 2013
Metastatic breast cancer blood test performs well
NHS Choices |  14 March 2013
14 September 2015 - by Isobel Steer 
A US startup called Pathway Genomics has launched the first commercial 'liquid biopsy' to identify cancerous mutations via a blood test...
1 September 2015 - by Dr Hannah Somers 
Scientists have developed a blood test that can predict several months in advance which breast cancer patients will relapse.
6 January 2014 - by Dr Rachel Montgomery 
An injection to prevent breast cancer by silencing a cancer-causing gene has shown early promise in mouse studies...
30 September 2013 - by David O'Rourke 
A new genetic test that can estimate the risk of breast cancer in women returning after surgery has been approved for use in the NHS....
28 May 2013 - by Chris Jacobs 
The news about Angelina Jolie opting for a double mastectomy to reduce her risk of breast cancer has undoubtedly raised concerns among women with a family history of the disease. Whilst this news has certainly raised awareness of hereditary cancer, there are two key points that it is important to emphasize...
15 July 2013 - by Julianna Photopoulos 
Scientists have developed a 'barcode' blood test that reads genetic changes to pick out the most aggressive prostate cancers...
4 March 2013 - by Daryl Ramai 
Leading technology groups team up with Cancer Research UK to develop a mobile phone app that will allow the public to sift through large amounts of genetic data in a bid to accelerate cancer research...
15 May 2012 - by Sarah Pritchard 
A DNA test for men with prostate cancer could indicate whether their cancer is likely to recur after treatment, and if so, how aggressively, say researchers from the University of Pittsburg School of Medicine, USA...
23 April 2012 - by Dr Linda Wijlaars 
Breast cancer can be reclassified into ten separate 'diseases' based on its genetic characteristics, according to scientists. Analysis of the DNA and RNA from almost 2,000 tumours identified ten genetically different subtypes of breast cancer with different survival outcomes. The information could be used to better predict the outcomes of the disease, as well as offer tailored treatment to patients...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.